ORION OYJ/ADR (OTCMKTS:ORINY) – Equities research analysts at Jefferies Financial Group reduced their FY2019 earnings estimates for shares of ORION OYJ/ADR in a research note issued to investors on Monday, February 11th. Jefferies Financial Group analyst J. Vane-Tempest now forecasts that the company will earn $0.80 per share for the year, down from their previous forecast of $0.89. Jefferies Financial Group also issued estimates for ORION OYJ/ADR’s FY2021 earnings at $0.80 EPS, FY2022 earnings at $0.97 EPS and FY2023 earnings at $1.01 EPS.
Separately, Zacks Investment Research downgraded shares of ORION OYJ/ADR from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 2nd.
Shares of OTCMKTS ORINY opened at $17.10 on Tuesday. The company has a market capitalization of $4.83 billion, a PE ratio of 18.79, a PEG ratio of 12.81 and a beta of 0.45. ORION OYJ/ADR has a 52-week low of $15.00 and a 52-week high of $20.38.
The business also recently disclosed an annual dividend, which will be paid on Friday, April 19th. Investors of record on Thursday, March 28th will be given a dividend of $0.669 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a yield of 3.91%. ORION OYJ/ADR’s dividend payout ratio (DPR) is 76.92%.
ORION OYJ/ADR Company Profile
Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.
See Also: Should You Consider an Index Fund?
Receive News & Ratings for ORION OYJ/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORION OYJ/ADR and related companies with MarketBeat.com's FREE daily email newsletter.